Lymphadenectomy

Study results from C. Rosendorff and colleagues update understanding of hypertrophy

Published in Medical Devices and Surgical Technology Week, September 27th, 2009

According to a study from the United States, "Reversal of left ventricular (LV) hypertrophy is an important goal of anti hypertensive therapy. This phase 3b study compared the ability of the angiotensin receptor blocker olmesartan medoxomil with the calcium channel blocker amlodipine besylate to induce regression of LV hypertrophy and vascular hypertrophy after achieving blood pressure (BP) goal."

"After a washout phase, 102 patients with hypertension and LV hypertrophy were randomized to olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day, or amlodipine 5 mg/day, up titrated to 10 mg/day, for up to 4 weeks until a BP goal of <140/90 mm Hg (<130/85 mm Hg for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week

Source: Medical Devices and Surgical Technology Week (2009-09-27)

More Articles from Medical Devices and Surgical Technology Week

American Heart Association
Simple test may identify stroke survivors at risk of another cardiovascular event
Massachusetts General Hospital
Cardiac biomarker levels strongly predict outcome of bypass surgery
Cancer Vaccines
Research by LA BioMeds Rowan T. Chlebowski, MD, PhD,
Ranked among the Milestones in a Century of Cancer Prevention
Dementia
Formal education lessens the impact of Alzheimers disease even if brain volume is already reduced
Immunology
Enabling microRNA Discoveries - LC Sciences tops 100th customer publication
Ostomy
New Data Supports ConvaTec Negative Pressure Wound Therapy
Case Series Published in June Issue of Ostomy Wound Management1
More from this issue of Medical Devices and Surgical Technology Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry